At a glance
- Originator Aventis
- Class Analgesics; Anti-inflammatories; Antirheumatics
- Mechanism of Action Cyclooxygenase inhibitors; Lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatic disorders
Most Recent Events
- 23 Jul 1998 No-Development-Reported for Rheumatic disorders in France (Unknown route)
- 22 Feb 1995 Phase-I clinical trials for Rheumatic disorders in France (Unknown route)